Anti-Lysine tRNA synthetase Antibody (7N990) is a Rabbit antibody targeting . Anti-Lysine tRNA synthetase Antibody (7N990) can be used in FCM,ICC/IF,IF,IHC-Fr,IHC-P,IP,WB.

IgG

7N990

Human,Mouse,Rat

1. 25 ug total protein per lane of various lysates (see on figure) probed with Lysine tRNA synthetase monoclonal antibody, unconjugated (TMAB-08475) at 1: 1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.
2. The Hela (H) cells were fixed with 4% PFA (10 min at r. T.) and then permeabilized with 90% ice-cold methanol for 20 min at -20℃, the cells then were incubated in 5% BSA to block non-specific protein-protein interactions (30 min at r. T.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green): Rabbit Anti-Lysine tRNA synthetase antibody (TMAB-08475, 1: 100); Isotype Control (orange): Rabbit IgG. Blank control (black): PBS. Acquisition of 20,000 events was performed.

WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:50-200,IF=1:100-500,IP=1:20-50,Flow-Cyt=1:50-100

Monoclonal

A synthesized peptide: human Lysine tRNA ligase

Human

KARS1

Lysine--tRNA ligase

Negative regulator in the hedgehog signaling pathway. Down-regulates GLI1-mediated transactivation of target genes. Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome. Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein. Negative regulator of beta-catenin signaling. Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full length form of GLI3 (GLI3FL). GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state. Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R. When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A).